Adoptive immunotherapy: New assay for the identification of T cells with optimal avidity

OncoImmunology

Volumn 2, Issue 10, 2013, Pages

  Weissbrich, Bianca ^a   Nauerth, Magdalena ^a   Busch, Dirk H ^a,b,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c DZIF National Centre for Infection Research   (Germany)

Author keywords

Avidity; CD8+ cytotoxic T cell; Koff rate; T cell; T cell receptor

Indexed keywords

MELANOMA ANTIGEN 3; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CELL ASSAY; CELL SELECTION; CLINICAL TRIAL (TOPIC); EX VIVO STUDY; HUMAN; LYMPHOCYTE TRANSFER; MOLECULAR RECOGNITION; PATIENT SAFETY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; REPRODUCIBILITY; T LYMPHOCYTE;

EID: 84890284340     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26199     Document Type: Article

References (10)

1. Stemberger C, Huster KM, Koffler M, Anderl F, Schiemann M, Wagner H, Busch DH. A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity 2007; 27:985- 97; PMID:18082432; http://dx.doi.org/10.1016/j. immuni.2007.10.012
2. Buchholz VR, Flossdorf M, Hensel I, Kretschmer L, Weissbrich B, Gräf P, Verschoor A, Schiemann M, Höfer T, Busch DH. Disparate individual fates compose robust CD8+ T cell immunity. Science 2013; 340:630-5; PMID:23493420; http://dx.doi.org/10.1126/science.1235454
3. Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two selfantigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162:989-94; PMID:9916724
4. Derby M, Alexander-Miller M, Tse R, Berzofsky J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 2001; 166:1690-7; PMID:11160212
5. Nauerth M, Weißbrich B, Knall R, Franz T, Dössinger G, Bet J, Paszkiewicz PJ, Pfeifer L, Bunse M, Uckert W, et al. TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci Transl Med 2013; 5:192ra87; PMID:23825303; http://dx.doi.org/10.1126/scitranslmed.3005958
6. Ozawa T, Tajiri K, Kishi H, Muraguchi A. Comprehensive analysis of the functional TCR repertoire at the single-cell level. Biochem Biophys Res Commun 2008; 367:820-5; PMID:18191637; http://dx.doi.org/10.1016/j.bbrc.2008.01.011
7. Dössinger G, Bunse M, Bet J, Albrecht J, Paszkiewicz PJ, Weißbrich B, Schiedewitz I, Henkel L, Schiemann M, Neuenhahn M, et al. MHC multimer-guided and cell culture-independent isolation of functional T cell receptors from single cells facilitates TCR identification for immunotherapy. PLoS One 2013; 8:e61384; PMID:23637823; http://dx.doi.org/10.1371/journal. pone.0061384
8. Hombrink P, Raz Y, Kester MG, de Boer R, Weißbrich B, von dem Borne PA, Busch DH, Schumacher TN, Falkenburg JH, Heemskerk MH. Mixed functional characteristics correlating with TCR-ligand koff -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire. Eur J Immunol 2013; PMID:23893393; http://dx.doi.org/10.1002/ eji.201343397
9. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29:917- 24; PMID:21282551; http://dx.doi.org/10.1200/ JCO.2010.32.2537
10. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 122:863- 71; PMID:23770775; http://dx.doi.org/10.1182/blood-2013-03-490565